8/F, 35 QRC Building, No.35 Queens Road, Central, Hong Kong
  • Cabometyx (Cabozantinib)

    Cabozantinib, developed by Exelixis Biopharmaceuticals, USA, is a broad-spectrum anticancer drug with multiple targets, including MET, VEGFR1/2/3, ROS1...

    Lung CancerLiver CancerKidney CancerThyroid Cancer
  • Retevmo (Selpercatinib)

    Retevmo is a kinase inhibitor indicated for the treatment of: 1) Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) ...

    Lung CancerThyroid Cancer
  • Of 1Page2Record